Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Experimental Neurology

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EXPNEUROL.2003.10.003PMID 14736509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease

  2001cited by this paper
• The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.

  2000cited by this paper
• Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.

  2000cited by this paper
• Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

  1999cited by this paper
• Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration.

  1999cited by this paper
• Growth/differentiation factor 5 and glial cell line‐derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease

  1998cited by this paper
• Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.

  1997cited by this paper
• In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF.

  1997cited by this paper
• Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease.

  1997cited by this paper
• Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery

  1997cited by this paper
• Glial cell line-derived neurotrophic factor reverses motor impairment in 16–17 month old rats

  1996cited by this paper
• Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s Disease

  1996cited by this paper
• Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult.

  1995cited by this paper
• Glial cell line‐derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons

  1995cited by this paper
• Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor‐β superfamily, on midbrain dopaminergic neurons

  1995cited by this paper
• Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.

  1995cited by this paper
• Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.

  1995cited by this paper
• Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

  1995cited by this paper
• Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

  1994cited by this paper
• Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra.

  1994cited by this paper
• Cloning and expression of recombinant human growth/differentiation factor 5.

  1994cited by this paper
• Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo

  1994cited by this paper
• A review of recent advances in stereology for quantifying neural structure

  1992cited by this paper
• Degeneration of the nigral dopamine neurons after 6-hydroxydopamine injection into the rat striatum.

  1991cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper

• GDF5 as a rejuvenating treatment for age-related neuromuscular failure.

  2024cites this paper
• The promise of the TGF-β superfamily as a therapeutic target for Parkinson's disease.

  2022cites this paper
• NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson’s Disease

  2021cites this paper
• Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson’s disease

  2021cites this paper
• Blockage of undesirable endocytosis of recombinant human growth/differentiation factor‐5 in Chinese hamster ovary cell cultures requires heparin analogs with specific chain lengths

  2021cites this paper
• STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5

  2020cites this paper
• Repulsive guidance molecules lock growth differentiation factor 5 in an inhibitory complex

  2020cites this paper
• Title The potential of neurotrophic factors for the treatment of Parkinson ' s disease

  2018cites this paper
• Biomarkers in Parkinson disease: studies on clinical, radiological and biological biomarkers

  2018cites this paper
• Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease

  2017cites this paper
• Romidepsin induces caspase-dependent cell death in human neuroblastoma cells.

  2017cites this paper
• Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease

  2015cites this paper
• Viral vector delivery of neurotrophic factors for Parkinson's disease therapy

  2015cites this paper
• Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier

  2015cites this paper
• Liver hydrolysate attenuates the sickness behavior induced by concanavalin A in mice.

  2015cites this paper
• Canonical BMP–Smad Signalling Promotes Neurite Growth in Rat Midbrain Dopaminergic Neurons

  2014cites this paper
• Growth Differentiation Factor 6 As a Putative Risk Factor in Neuromuscular Degeneration

  2014cites this paper
• Roles for the TGFβ Superfamily in the Development and Survival of Midbrain Dopaminergic Neurons

  2014cites this paper
• Comparison of GDF5 and GDNF as neuroprotective factors for postnatal dopamine neurons in ventral mesencephalic cultures

  2014cites this paper
• 6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo.

  2014cites this paper
• A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.

  2014cites this paper
• Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease

  2014cites this paper
• Duration-dependence of the effect of treadmill exercise on hyperactivity in attention deficit hyperactivity disorder rats

  2014cites this paper
• Midbrain dopaminergic neurons: a review of the molecular circuitry that regulates their development.

  2013cites this paper
• Swimming exercise alleviates the symptoms of attention-deficit hyperactivity disorder in spontaneous hypertensive rats.

  2013cites this paper
• Expression and function of APRIL and GDF-5 in the developing hippocampus

  2013cites this paper
• BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons.

  2013cites this paper
• Characterisation of the role of canonical BMP-Smad 1/5/8 signalling in the development of ventral midbrain dopaminergic neurons

  2013cites this paper
• Intranasal delivery of growth differentiation factor 5 to the central nervous system

  2012cites this paper
• GDF-5 and BMP-2 regulate bone cell differentiation by gene expression of MSX1, MSX2, Dlx5, and Runx2 and influence OCN gene expression in vitro.

  2012cites this paper
• Neurotrophic Effects of Growth/Differentiation Factor 5 in a Neuronal Cell Line

  2012cites this paper
• Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease

  2012cites this paper
• Novel neurotrophic treatments in rats and toxin sensitivity of genetically modified mice in the unilateral 6 OHDA model of Parkinson's disease

  2012cites this paper
• The neuroprotective effect of modified Yeoldahanso-tang via autophagy enhancement in models of Parkinson's disease.

  2011cites this paper
• Treadmill exercise and methylphenidate ameliorate symptoms of attention deficit/hyperactivity disorder through enhancing dopamine synthesis and brain-derived neurotrophic factor expression in spontaneous hypertensive rats.

  2011cites this paper
• The potential of neurotrophic factors for the treatment of Parkinson's disease

  2011cites this paper
• Towards New Therapies for Parkinson's Disease

  2011cites this paper
• Neurotrophic factors for the treatment of Parkinson's disease.

  2011cites this paper
• Cell- and gene-therapy approaches to inner ear repair.

  2011cites this paper
• Hypothermia alleviates hypoxic ischemia-induced dopamine dysfunction and memory impairment in rats

  2011cites this paper
• Neuroprotective and Anti-inflammatory Effects of Bee Venom Acupuncture on MPTP-induced Mouse

  2010cites this paper
• Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo

  2010cites this paper
• Effects of Hydroxysafflor Yellow A in the Attenuation of MPTP Neurotoxicity in Mice

  2009cites this paper
• NOVEL CDNF/MANF PROTEIN FAMILY: MOLECULAR STRUCTURE, EXPRESSION AND NEUROTROPHIC ACTIVITY

  2009cites this paper
• Brachydactyly type A2 associated with a defect in proGDF5 processing.

  2008cites this paper
• TAT-PAX6 protein transduction in neural progenitor cells: a novel approach for generation of dopaminergic neurones in vitro.

  2008cites this paper
• Progress in Parkinson's disease-where do we stand?

  2008cites this paper
• Differential effects of GDF5 on the medial and lateral rat ventral mesencephalon.

  2007cites this paper
• GnRH-Mediated DAN Production Regulates the Transcription of the GnRH Receptor in Gonadotrope Cells

  2007cites this paper
• Combination of engineered neural cell adhesion molecules and GDF-5 for improved neurite extension in nerve guide concepts.

  2006cites this paper
• Effect of Acupuncture on 6-Hydroxydopamine-induced Nigrostriatal Dopaminergic Neuronal Cell Death in Rats

  2006cites this paper
• Effect of acupuncture on 6-hydroxydopamine-induced nigrostratal dopaminergic neuronal cell death in rats.

  2005cites this paper
• The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment

  2005cites this paper
• Dementia in Parkinson’s disease – causes and treatment Review: Dementia in Parkinson’s disease: cause and treatment (pp 399–404)

  2004cites this paper
• Expression of growth differentiation factor-5 in the developing and adult rat brain.

  2004cites this paper
• Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro

  2004cites this paper